ITIF2024以史为鉴远观未来美国必须确保其生物制药产业全球领导地位的原因分析报告英文版63页

itif.org Not Again: Why the United States Can’t Afford to Lose Its Biopharma Industry SANDRA BARBOSU | FEBRUARY 2024 America’s leadership in advanced-technology industries can never be taken for granted, as evidenced by its losses in telecommunications equipment, semiconductors, televisions, solar panels, and chemicals. Policymakers must recognize what went wrong in those cases to avoid a similar industrial decline in the biopharmaceutical industry. KEY TAKEAWAYS  The biopharmaceutical industry is crucial to the U.S. economy. America leads this sector globally thanks to its large domestic market, robust IP protections, limits on government drug price setting, supportive science policies, and supportive innovation clusters.  But as China commits to achieve biopharmaceutical leadership, the United States is neglecting its position, hamstringing the industry with government-imposed price controls and policies that weaken foundational IP protections.  Absent sustained policies that